Compare · RVMD vs SOPH
RVMD vs SOPH
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $45.31B, about 61.5x SOPH ($736.4M).
- Over the past year, RVMD is up 466.1% and SOPH is up 157.9% - RVMD leads by 308.2 points.
- SOPH has been more active in the news (14 items in the past 4 weeks vs 11 for RVMD).
- RVMD has more recent analyst coverage (25 ratings vs 14 for SOPH).
- Company
- Revolution Medicines Inc.
- SOPHiA GENETICS SA
- Price
- $211.21-0.17%
- $8.64+2.49%
- Market cap
- $45.31B
- $736.4M
- 1M return
- +12.27%
- +53.19%
- 1Y return
- +466.09%
- +157.91%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2021
- News (4w)
- 11
- 14
- Recent ratings
- 25
- 14
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest RVMD
- General Counsel Cislini Jeff exercised 56,280 shares at a strike of $20.00 and sold $11,904,247 worth of shares (56,894 units at $209.24) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 55,907 units (SEC Form 4)
- Officer Goldsmith Mark A exercised 80,000 shares at a strike of $4.73 and sold $17,991,107 worth of shares (86,000 units at $209.20) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- SEC Form SCHEDULE 13G filed by Revolution Medicines Inc.
- BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SOPH
- SEC Form 144 filed by SOPHiA GENETICS SA
- Chief People Officer Valente Manuela exercised 10,000 units of Ordinary Shares at a strike of $3.20 and sold $79,439 worth of Ordinary Shares (10,000 units at $7.94) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu sold $163,482 worth of Ordinary Shares (20,000 units at $8.17) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,887 units (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu sold $30,076 worth of Ordinary Shares (4,000 units at $7.52) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 586,887 units (SEC Form 4)
- Chief Medical Officer Menu Philippe sold $37,580 worth of Ordinary Shares (5,000 units at $7.52) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 218,387 units (SEC Form 4)
- Executive Chairman Camblong Jurgi sold $209,209 worth of Ordinary Shares (28,500 units at $7.34) as part of a pre-agreed trading plan, decreasing direct ownership by 0.82% to 3,444,322 units (SEC Form 4)
- Chief Technology Officer Verma Abhimanyu sold $38,000 worth of Ordinary Shares (5,000 units at $7.60) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 182,171 units (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu exercised 10,000 units of Ordinary Shares at a strike of $3.28 and sold $144,924 worth of Ordinary Shares (20,000 units at $7.25) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 590,887 units (SEC Form 4)
- Executive Chairman Camblong Jurgi sold $138,412 worth of Ordinary Shares (20,000 units at $6.92) as part of a pre-agreed trading plan, decreasing direct ownership by 0.57% to 3,472,822 units (SEC Form 4)
- Chief Scientific Officer Xu Zhenyu sold $69,168 worth of Ordinary Shares (10,000 units at $6.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 600,887 units (SEC Form 4)